Nalfurafine (BioDeep_00000837753)
代谢物信息卡片
化学式: C28H32N2O5 (476.2311102)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN(C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)C=CC7=COC=C7
InChI: InChI=1S/C28H32N2O5/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3/b7-4+/t20-,22-,26+,27+,28-/m1/s1
描述信息
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:136019
- PubChem: 6445230
- DrugBank: DB13471
- ChEMBL: CHEMBL267495
- ChEMBL: CHEMBL490665
- CAS: 152657-84-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ping Zhang, Shilong Xiang, Bicheng Liu, Xiaohui Wang, Xiaoping Yang, Chaoyang Ye, Zunsong Wang, Yanlin Li, Li Zhou, Caili Wang, Hongbo Li, Jian Huang, Ai Peng, Xiaoping Wang, Deguang Wang, Jie Xiao, Wenli Chen, Hong Cheng, Nan Mao, Jianqin Wang, Lin Yang, Jianghua Chen. Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients.
Renal failure.
2023 Dec; 45(1):2175590. doi:
10.1080/0886022x.2023.2175590. [PMID: 36856148] - Jacob K Meariman, Jane C Sutphen, Juan Gao, Daniel R Kapusta. Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.
Hypertension (Dallas, Tex. : 1979).
2022 02; 79(2):379-390. doi:
10.1161/hypertensionaha.121.18503. [PMID: 34852633] - Yan Zhou, Kevin Freeman, Vincent Setola, Danni Cao, Shane Kaski, Mary Jeanne Kreek, Lee-Yuan Liu-Chen. Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.
Handbook of experimental pharmacology.
2022; 271(?):137-162. doi:
10.1007/164_2021_443. [PMID: 33834276] - Amelia Dunn, Kyle Windisch, Ariel Ben-Ezra, Phillip Pikus, Michelle Morochnik, Jose Erazo, Brian Reed, Mary Jeanne Kreek. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
Psychopharmacology.
2020 Aug; 237(8):2405-2418. doi:
10.1007/s00213-020-05543-7. [PMID: 32435819] - Hidetomo Nakamoto, Takehito Kobayashi, Toru Noguchi, Takeru Kusano, Keigo Ashitani, Hiroyuki Imaeda, Michiko Maezono. Prevalence and Severity of Itching in Patients with End-Stage Renal Disease: Treatment with Nalfurafine Hydrochloride.
Blood purification.
2019; 47 Suppl 2(?):45-49. doi:
10.1159/000496637. [PMID: 30943482] - Minami Yagi, Atsushi Tanaka, Tadashi Namisaki, Atsushi Takahashi, Masanori Abe, Akira Honda, Yasushi Matsuzaki, Hiromasa Ohira, Hitoshi Yoshiji, Hajime Takikawa. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Journal of gastroenterology.
2018 Oct; 53(10):1151-1158. doi:
10.1007/s00535-018-1465-z. [PMID: 29663077] - Hugh C Rayner, Maria Larkina, Mia Wang, Matthew Graham-Brown, Sabine N van der Veer, Tevfik Ecder, Takeshi Hasegawa, Werner Kleophas, Brian A Bieber, Francesca Tentori, Bruce M Robinson, Ronald L Pisoni. International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Clinical journal of the American Society of Nephrology : CJASN.
2017 Dec; 12(12):2000-2007. doi:
10.2215/cjn.03280317. [PMID: 28923831] - Kenya Kamimura, Takeshi Yokoo, Hiroteru Kamimura, Akira Sakamaki, Satoshi Abe, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
PloS one.
2017; 12(6):e0178991. doi:
10.1371/journal.pone.0178991. [PMID: 28604788] - Akihiro Ando, Shinichiro Sasago, Yoshihiro Ohzone, Yohei Miyamoto. Drug-Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-Glycoprotein.
European journal of drug metabolism and pharmacokinetics.
2016 Oct; 41(5):549-58. doi:
10.1007/s13318-015-0286-1. [PMID: 26058994] - Thomas Mettang. Uremic Itch Management.
Current problems in dermatology.
2016; 50(?):133-41. doi:
10.1159/000446056. [PMID: 27578082] - Thomas Mettang, Andreas E Kremer. Uremic pruritus.
Kidney international.
2015 Apr; 87(4):685-91. doi:
10.1038/ki.2013.454. [PMID: 24402092] - Tasuku Akiyama, Mirela Iodi Carstens, Dorothea Piecha, Sonja Steppan, Earl Carstens. Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice.
Acta dermato-venereologica.
2015 Feb; 95(2):147-50. doi:
10.2340/00015555-1879. [PMID: 24890341] - Hiroo Kumagai, Toshiya Ebata, Kenji Takamori, Katsumasa Miyasato, Taro Muramatsu, Hidetomo Nakamoto, Masanao Kurihara, Tomoji Yanagita, Hiromichi Suzuki. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
American journal of nephrology.
2012; 36(2):175-83. doi:
10.1159/000341268. [PMID: 22868684] - NULL. Molecule of the Month. Nalfurafine hydrochloride.
Drug news & perspectives.
2009 Dec; 22(10):619. doi:
10.1358/dnp.2009.22.10.1443396. [PMID: 20140281] - Saadet Inan, Alan Cowan. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.
Pharmacology, biochemistry, and behavior.
2006 Sep; 85(1):39-43. doi:
10.1016/j.pbb.2006.07.004. [PMID: 16919318] - James A Delmez. Efficacy and safety of a new kappa-opioid receptor agonist for the treatment of uremic pruritus.
Nature clinical practice. Nephrology.
2006 Jul; 2(7):358-9. doi:
10.1038/ncpneph0202. [PMID: 16932462] - Hideo Umeuchi, Yumi Kawashima, Christopher A Aoki, Takahiro Kurokawa, Kaoru Nakao, Masatoshi Itoh, Kentaro Kikuchi, Takashi Kato, Kiyoshi Okano, M Eric Gershwin, Hiroshi Miyakawa. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
European journal of pharmacology.
2005 Aug; 518(2-3):133-9. doi:
10.1016/j.ejphar.2005.06.019. [PMID: 16055114]